These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38851203)

  • 41. Safety and Efficacy of 177 Lu-DOTATATE in Children and Young Adult Population : A Single-Center Experience.
    Aggarwal P; Satapathy S; Sood A; Singh H; Mittal BR; Lal S; Gupta R; Das CK; Yadav TD; Walia R
    Clin Nucl Med; 2024 Jul; 49(7):e312-e318. PubMed ID: 38769655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
    Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Salvage peptide receptor radionuclide therapy with [
    van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of
    Clement D; Navalkissoor S; Srirajaskanthan R; Courbon F; Dierickx L; Eccles A; Lewington V; Mitjavila M; Percovich JC; Lequoy B; He B; Folitar I; Ramage J
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3529-3537. PubMed ID: 35389069
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease.
    Thakral P; Sen I; Das SS; Manda D; Cb V; Malik D
    Br J Radiol; 2021 Oct; 94(1126):20210403. PubMed ID: 34357794
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness and Safety of Retreatment with
    Delpassand ES; Yazdi SM; Ghantoji S; Nakasato A; Strickland C; Nunez R; Shafie A; Cork S; Byrne C; Tang J; Patel J
    J Nucl Med; 2024 May; 65(5):746-752. PubMed ID: 38514088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
    Lau SC; Abdel-Rahman O; Cheung WY
    Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience.
    Piscopo L; Zampella E; Volpe F; Gaudieri V; Nappi C; Di Donna E; Clemente S; Varallo A; Scaglione M; Cuocolo A; Klain M
    Curr Oncol; 2024 Sep; 31(9):5617-5629. PubMed ID: 39330044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With
    Strosberg J; Wolin E; Chasen B; Kulke M; Bushnell D; Caplin M; Baum RP; Kunz P; Hobday T; Hendifar A; Oberg K; Sierra ML; Thevenet T; Margalet I; Ruszniewski P; Krenning E;
    J Clin Oncol; 2018 Sep; 36(25):2578-2584. PubMed ID: 29878866
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative SPECT/CT Metrics in Early Prediction of [
    Tuncer O; Steinberger D; Steiner J; Hinojos M; Rhee SY; Humphrey B; Jafari F; Cayci Z
    J Nucl Med; 2024 Oct; 65(10):1584-1590. PubMed ID: 39266296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response.
    Vaughan E; Machta J; Walker M; Toumpanakis C; Caplin M; Navalkissoor S
    Br J Radiol; 2018 Nov; 91(1091):20180041. PubMed ID: 29513039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Guidance on
    Abbott A; Sakellis CG; Andersen E; Kuzuhara Y; Gilbert L; Boyle K; Kulke MH; Chan JA; Jacene HA; Van den Abbeele AD
    J Nucl Med Technol; 2018 Sep; 46(3):237-244. PubMed ID: 30076245
    [No Abstract]   [Full Text] [Related]  

  • 57. 177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN Study.
    Mileva M; Van Bogaert C; Marin G; Danieli R; Artigas C; Levillain H; Ameye L; Taraji-Schiltz L; Stathopoulos K; Wimana Z; Hendlisz A; Flamen P; Karfis I
    Clin Nucl Med; 2024 Sep; 49(9):847-853. PubMed ID: 38914016
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and outcomes of
    Lin E; Chen T; Little A; Holliday L; Roach P; Butler P; Hosking E; Bailey E; Elison B; Currow D
    Intern Med J; 2019 Oct; 49(10):1268-1277. PubMed ID: 31062490
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of peptide receptor radionuclide therapy with
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
    Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
    [No Abstract]   [Full Text] [Related]  

  • 60. Radionuclide Therapy for Neuroendocrine Tumors.
    Cives M; Strosberg J
    Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.